Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Phase 3
Recruiting
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: SeralutinibDevice: Gereic Dry Powder Inhaler
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- GB002, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06274801
- Locations
- 🇩🇪
Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg Zentrum für pulmonale Hypertonie, Heidelberg, Germany
🇩🇪Klinikum Würzburg Mitte gGmbH Medizinische Klinik mit Schwerpunkt Pneumologie und Beatmungsmedizin, Würzburg, Germany
🇬🇷AHEPA University General Hospital of Thessaloniki, 1st Cardiology Clinic, Thessaloníki, Greece
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Phase 3
Recruiting
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- GB002, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT05934526
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Valley Advanced Lung Diseases Institute, Fresno, California, United States
🇺🇸Keck Medical Center of USC, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath